{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:46:10Z","timestamp":1784328370810,"version":"3.55.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Novaliq GmbH"},{"name":"Novaliq GmbH"},{"name":"Novaliq GmbH"},{"name":"Novaliq GmbH"},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Declare DSMC member"},{"name":"Novaliq GmbH"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>The ESSENCE-2 Open-Label Extension study aimed to demonstrate long-term safety, tolerability, and efficacy of a novel water-free, nonpreserved topical cyclosporine 0.1% ophthalmic solution (US brand name VEVYE) for patients with dry eye disease (DED).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This was a Phase 3, prospective, multicenter, open-label, clinical study. All patients received cyclosporine 0.1% ophthalmic solution and dosed each eye twice a day for 52 weeks. Primary safety end points were ocular and nonocular adverse events (AEs). Secondary safety end points included visual acuity, biomicroscopy, intraocular pressure, and dilated fundoscopy. Efficacy end points, such as total corneal fluorescein staining (tCFS) score (National Eye Institute [NEI] Scale), ocular symptoms (visual analog scale [VAS]), and Schirmer tear test, were also assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 202 patients were enrolled from the ESSENCE-2 study. At week 52, 175 patients (86.6%) completed ESSENCE-2 open-label extension. A total of 55 patients (27.5%) reported 74 ocular treatment-emergent adverse events (TEAEs). The most common ocular AE was instillation site pain (6.5%), which was of mild intensity in all cases. Patients showed statistically significant improvements in all prespecified efficacy end points compared with baseline at each visit. Corneal staining improvements were early and stabilized over time while tear production improved continuously. Symptomatology improvement followed these effects with scores reaching a minimum after 1 year of treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The water-free cyclosporine 0.1% ophthalmic solution was safe and well tolerated during long-term use. The results demonstrated sustained 1-year efficacy, in both signs and symptoms of DED, and may help understand short and long-term healing dynamics in a predominant inflammatory DED population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ico.0000000000003567","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T18:00:29Z","timestamp":1716314429000},"page":"692-700","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE"],"prefix":"10.1097","volume":"44","author":[{"given":"David L.","family":"Wirta","sequence":"first","affiliation":[{"name":"Eye Research Foundation, Newport Beach, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Galor","sequence":"additional","affiliation":[{"name":"Miami Veterans Administration Medical Center and Bascom Palmer Eye Institute, University of Miami, Miami, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Aune","sequence":"additional","affiliation":[{"name":"Oculus Research Inc., Garner, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Vollmer","sequence":"additional","affiliation":[{"name":"Vita Eye Clinic, Shelby, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Liang","sequence":"additional","affiliation":[{"name":"Center for Sight, Las Vegas, NV; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice S.","family":"Meides","sequence":"additional","affiliation":[{"name":"Novaliq GmbH, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2049-2076","authenticated-orcid":false,"given":"Sonja","family":"Kr\u00f6sser","sequence":"additional","affiliation":[{"name":"Novaliq GmbH, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"R1-20250505","doi-asserted-by":"crossref","first-page":"P286","DOI":"10.1016\/j.ophtha.2018.10.023","article-title":"Dry eye syndrome preferred practice Pattern\u00ae","volume":"126","author":"Akpek","year":"2019","journal-title":"Ophthalmology"},{"key":"R2-20250505","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2147\/OPTH.S228070","article-title":"A review of topical cyclosporine A formulations-A disease-modifying agent for keratoconjunctivitis sicca","volume":"14","author":"Jerkins","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"R3-20250505","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"R4-20250505","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejpb.2014.05.009","article-title":"Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery","volume":"88","author":"Dutescu","year":"2014","journal-title":"Eur J Pharm Biopharm"},{"key":"R5-20250505","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2018.01.019","article-title":"Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs","volume":"538","author":"Agarwal","year":"2018","journal-title":"Int J Pharm"},{"key":"R6-20250505","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00417-016-3572-y","article-title":"A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye","volume":"255","author":"Gehlsen","year":"2017","journal-title":"Graefes Clin Exp Ophthalmol"},{"key":"R7-20250505","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jtos.2019.02.010","article-title":"Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics","volume":"17","author":"Agarwal","year":"2019","journal-title":"Ocul Surf"},{"key":"R8-20250505","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejpb.2023.05.005","article-title":"Preclinical characterization of water-free cyclosporine eye drops - Factors impacting ocular penetration ex vivo and in vivo","volume":"188","author":"Agarwal","year":"2023","journal-title":"Eur J Pharm Biopharm"},{"key":"R9-20250505","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ophtha.2019.01.024","article-title":"A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease","volume":"126","author":"Wirta","year":"2019","journal-title":"Ophthalmology"},{"key":"R10-20250505","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/ICO.0000000000002633","article-title":"A water-free 0.1% cyclosporine A solution for treatment of dry eye disease: results of the randomized phase 2B\/3 ESSENCE study","volume":"40","author":"Sheppard","year":"2021","journal-title":"Cornea"},{"key":"R11-20250505","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaophthalmol.2023.0709","article-title":"Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of moderate to severe dry eye disease: the ESSENCE-2 randomized clinical trial","volume":"141","author":"Akpek","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"R12-20250505","article-title":"Efficacy of a water-free cyclosporine ophthalmic solution for the treatment of dry eye disease in patients with or without cataract","author":"Akpek","year":"2023"},{"key":"R14-20250505","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5455\/medarh.2021.75.144-148","article-title":"Mask-associated dry eye during COVID-19 pandemic-how face masks contribute to dry eye disease symptoms","volume":"75","author":"Krolo","year":"2021","journal-title":"Med Arch"},{"key":"R15-20250505","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40123-022-00487-x","article-title":"Real-world effectiveness, tolerability and safety of cyclosporine A 0.1% cationic emulsion in severe keratitis and dry eye treatment","volume":"11","author":"Geerling","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R16-20250505","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/ICO.0000000000000803","article-title":"Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study","volume":"35","author":"Donnenfeld","year":"2016","journal-title":"Cornea"},{"key":"R17-20250505","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2147\/OPTH.S226168","article-title":"Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye","volume":"13","author":"White","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"R18-20250505","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"R20-20250505","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"R21-20250505","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","article-title":"A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease","volume":"126","author":"Goldberg","year":"2019","journal-title":"Ophthalmology"},{"key":"R22-20250505","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s40123-022-00516-9","article-title":"Selective pharmacologic therapies for dry eye disease treatment: efficacy, tolerability, and safety data review from preclinical studies and pivotal trials","volume":"11","author":"Shen Lee","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R23-20250505","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jamaophthalmol.2021.3943","article-title":"Efficacy of lifitegrast ophthalmic solution, 5.0%, in patients with moderate to severe dry eye disease: a post hoc analysis of 2 randomized clinical trials","volume":"139","author":"Holland","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"R24-20250505","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.4103\/IJO.IJO_2808_22","article-title":"Aqueous-deficient dry eye disease: preferred practice pattern guidelines on clinical approach, diagnosis, and management","volume":"71","author":"Donthineni","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R25-20250505","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1167\/iovs.13-12370","article-title":"Corneal nerve structure and function in patients with non-sjogren dry eye: clinical correlations","volume":"54","author":"Labb\u00e9","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R26-20250505","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/aos.13844","article-title":"Role of corneal nerves in ocular surface homeostasis and disease","volume":"97","author":"Labetoulle","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"R27-20250505","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtos.2017.10.001","article-title":"Neuropathic pain and dry eye","volume":"16","author":"Galor","year":"2018","journal-title":"Ocul Surf"},{"key":"R28-20250505","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/ceo.12898","article-title":"Increased corneal sub-basal nerve density in patients with Sj\u00f6gren syndrome treated with topical cyclosporine A","volume":"45","author":"Levy","year":"2017","journal-title":"Clin Exp Ophthalmol"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000003567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T20:04:57Z","timestamp":1746475497000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000003567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000003567","relation":{},"ISSN":["0277-3740","1536-4798"],"issn-type":[{"value":"0277-3740","type":"print"},{"value":"1536-4798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"2024-03-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}